A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma

Byoung Chul Cho, Eun Hee Kim, Hye Jin Choi, Joo Hang Kim, Jae Kyung Roh, Hyun Cheol Chung, Joong Bae Ahn, Jong Doo Lee, Jong Tae Lee, Nae Choon Yoo, Joo Hyuk Sohn

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Percutaneous approaches, such as percutaneous ethanol injection and radiofrequency ablation, have been most widely used for hepatocellular carcinoma patients who were not eligible for singery. New technologies to improve the efficacy are currently needed. 166Holmium is a neutron activated radionuclide, and has several beneficial radiophysical characteristics for internal radiation therapy. 166Holmium-Chitosan complex, in which chitosan is chelated with 166Holmium, was developed as a radiopharmaceutical for cancer therapy. We have conducted a pilot study to evaluate the clinical efficacy of transarterial administration of 166Holmium-Chitosan complex in patients with a single and small (< 3 cm) hepatocellular carcinoma. 166Holmium-Chitosan complex, at a dose of 20 mCi per cm of tumor mass-diameter, was administered through the artery that directly fed the tumor. Twelve patients were treated with a median follow-up duration of 26 (range; 12-61) months. The tumor diameter ranged between 1.5 and 2.5 cm. Ten patients (83%) had complete response and two (17%) had partial response. The median complete response duration was not reached. The median AFP level declined from 83.8 to 8.3 ng/mL within 2 months after treatment. No grade III/IV toxicity was observed. Grade I and II toxicities were observed in four patients (2 abdominal pain. 1 fever, and 1 AST/ALT elevation). No toxic death occurred. This preliminary study shows a promising and durable complete response rate with an acceptable safety profile. Further studies with greater accrual of patients are warranted.

Original languageEnglish
Pages (from-to)799-805
Number of pages7
JournalYonsei medical journal
Volume46
Issue number6
DOIs
Publication statusPublished - 2005 Dec

Fingerprint

Chitosan
Hepatocellular Carcinoma
Injections
Neoplasms
Therapeutics
Radiopharmaceuticals
Poisons
Neutrons
Radioisotopes
Abdominal Pain
Fever
Ethanol
Radiotherapy
Arteries
Technology
Safety

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Cho, Byoung Chul ; Kim, Eun Hee ; Choi, Hye Jin ; Kim, Joo Hang ; Roh, Jae Kyung ; Chung, Hyun Cheol ; Ahn, Joong Bae ; Lee, Jong Doo ; Lee, Jong Tae ; Yoo, Nae Choon ; Sohn, Joo Hyuk. / A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. In: Yonsei medical journal. 2005 ; Vol. 46, No. 6. pp. 799-805.
@article{8ceb657c0c6e457682812220d8d25986,
title = "A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma",
abstract = "Percutaneous approaches, such as percutaneous ethanol injection and radiofrequency ablation, have been most widely used for hepatocellular carcinoma patients who were not eligible for singery. New technologies to improve the efficacy are currently needed. 166Holmium is a neutron activated radionuclide, and has several beneficial radiophysical characteristics for internal radiation therapy. 166Holmium-Chitosan complex, in which chitosan is chelated with 166Holmium, was developed as a radiopharmaceutical for cancer therapy. We have conducted a pilot study to evaluate the clinical efficacy of transarterial administration of 166Holmium-Chitosan complex in patients with a single and small (< 3 cm) hepatocellular carcinoma. 166Holmium-Chitosan complex, at a dose of 20 mCi per cm of tumor mass-diameter, was administered through the artery that directly fed the tumor. Twelve patients were treated with a median follow-up duration of 26 (range; 12-61) months. The tumor diameter ranged between 1.5 and 2.5 cm. Ten patients (83{\%}) had complete response and two (17{\%}) had partial response. The median complete response duration was not reached. The median AFP level declined from 83.8 to 8.3 ng/mL within 2 months after treatment. No grade III/IV toxicity was observed. Grade I and II toxicities were observed in four patients (2 abdominal pain. 1 fever, and 1 AST/ALT elevation). No toxic death occurred. This preliminary study shows a promising and durable complete response rate with an acceptable safety profile. Further studies with greater accrual of patients are warranted.",
author = "Cho, {Byoung Chul} and Kim, {Eun Hee} and Choi, {Hye Jin} and Kim, {Joo Hang} and Roh, {Jae Kyung} and Chung, {Hyun Cheol} and Ahn, {Joong Bae} and Lee, {Jong Doo} and Lee, {Jong Tae} and Yoo, {Nae Choon} and Sohn, {Joo Hyuk}",
year = "2005",
month = "12",
doi = "10.3349/ymj.2005.46.6.799",
language = "English",
volume = "46",
pages = "799--805",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. / Cho, Byoung Chul; Kim, Eun Hee; Choi, Hye Jin; Kim, Joo Hang; Roh, Jae Kyung; Chung, Hyun Cheol; Ahn, Joong Bae; Lee, Jong Doo; Lee, Jong Tae; Yoo, Nae Choon; Sohn, Joo Hyuk.

In: Yonsei medical journal, Vol. 46, No. 6, 12.2005, p. 799-805.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma

AU - Cho, Byoung Chul

AU - Kim, Eun Hee

AU - Choi, Hye Jin

AU - Kim, Joo Hang

AU - Roh, Jae Kyung

AU - Chung, Hyun Cheol

AU - Ahn, Joong Bae

AU - Lee, Jong Doo

AU - Lee, Jong Tae

AU - Yoo, Nae Choon

AU - Sohn, Joo Hyuk

PY - 2005/12

Y1 - 2005/12

N2 - Percutaneous approaches, such as percutaneous ethanol injection and radiofrequency ablation, have been most widely used for hepatocellular carcinoma patients who were not eligible for singery. New technologies to improve the efficacy are currently needed. 166Holmium is a neutron activated radionuclide, and has several beneficial radiophysical characteristics for internal radiation therapy. 166Holmium-Chitosan complex, in which chitosan is chelated with 166Holmium, was developed as a radiopharmaceutical for cancer therapy. We have conducted a pilot study to evaluate the clinical efficacy of transarterial administration of 166Holmium-Chitosan complex in patients with a single and small (< 3 cm) hepatocellular carcinoma. 166Holmium-Chitosan complex, at a dose of 20 mCi per cm of tumor mass-diameter, was administered through the artery that directly fed the tumor. Twelve patients were treated with a median follow-up duration of 26 (range; 12-61) months. The tumor diameter ranged between 1.5 and 2.5 cm. Ten patients (83%) had complete response and two (17%) had partial response. The median complete response duration was not reached. The median AFP level declined from 83.8 to 8.3 ng/mL within 2 months after treatment. No grade III/IV toxicity was observed. Grade I and II toxicities were observed in four patients (2 abdominal pain. 1 fever, and 1 AST/ALT elevation). No toxic death occurred. This preliminary study shows a promising and durable complete response rate with an acceptable safety profile. Further studies with greater accrual of patients are warranted.

AB - Percutaneous approaches, such as percutaneous ethanol injection and radiofrequency ablation, have been most widely used for hepatocellular carcinoma patients who were not eligible for singery. New technologies to improve the efficacy are currently needed. 166Holmium is a neutron activated radionuclide, and has several beneficial radiophysical characteristics for internal radiation therapy. 166Holmium-Chitosan complex, in which chitosan is chelated with 166Holmium, was developed as a radiopharmaceutical for cancer therapy. We have conducted a pilot study to evaluate the clinical efficacy of transarterial administration of 166Holmium-Chitosan complex in patients with a single and small (< 3 cm) hepatocellular carcinoma. 166Holmium-Chitosan complex, at a dose of 20 mCi per cm of tumor mass-diameter, was administered through the artery that directly fed the tumor. Twelve patients were treated with a median follow-up duration of 26 (range; 12-61) months. The tumor diameter ranged between 1.5 and 2.5 cm. Ten patients (83%) had complete response and two (17%) had partial response. The median complete response duration was not reached. The median AFP level declined from 83.8 to 8.3 ng/mL within 2 months after treatment. No grade III/IV toxicity was observed. Grade I and II toxicities were observed in four patients (2 abdominal pain. 1 fever, and 1 AST/ALT elevation). No toxic death occurred. This preliminary study shows a promising and durable complete response rate with an acceptable safety profile. Further studies with greater accrual of patients are warranted.

UR - http://www.scopus.com/inward/record.url?scp=30644465982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644465982&partnerID=8YFLogxK

U2 - 10.3349/ymj.2005.46.6.799

DO - 10.3349/ymj.2005.46.6.799

M3 - Article

C2 - 16385656

AN - SCOPUS:30644465982

VL - 46

SP - 799

EP - 805

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -